Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 Days Payable is 101.01 as of Dec. 2025, which is 5% below its 10-year median of 106.64. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 65.1% on this metric.
The historical rank and industry rank for WuXi XDC Cayman's Days Payable or its related term are showing as below:
HKSE:02268'
s Days Payable Range Over the Past 10 Years
Min: 18.79 Med: 106.64 Max: 129.66
Current: 102.37
During the past 6 years, WuXi XDC Cayman's highest Days Payable was 129.66. The lowest was 18.79. And the median was 106.64.
HKSE:02268's Days Payable is ranked better than 65.1% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.785
vs HKSE:02268: 102.37
WuXi XDC Cayman's Days Payable
increased
from Dec. 2024 (91.76) to Dec. 2025 (101.01).
It may suggest that WuXi XDC Caymandelayed paying its suppliers.
The historical data trend for WuXi XDC Cayman's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02268 vs TMO, DHR, NTRA: Days Payable Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Days Payable distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
WuXi XDC Cayman's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) has a Days Payable of 101.01 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 106.64. Over the past decade, WuXi XDC Cayman's Days Payable has ranged from 18.79 to 129.66. According to the industry distribution chart, WuXi XDC Cayman ranks #67 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 34.9%.
Is WuXi XDC Cayman's Days Payable too high?
WuXi XDC Cayman's current Days Payable of 101.01 is near median its 10-year median of 106.64. Over the past 10 years, this metric has ranged from a low of 18.79 to a high of 129.66. The Medical Diagnostics & Research industry median Days Payable is 65.79. WuXi XDC Cayman's value of 101.01 is 53.5% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #67 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #67 out of 192 companies for Days Payable. This puts WuXi XDC Cayman in the upper half of its industry. The industry median Days Payable is 65.79. WuXi XDC Cayman's value of 101.01 is 53.5% above this benchmark. Historically, WuXi XDC Cayman's own Days Payable has ranged from 18.79 to 129.66 over the past decade. While the company's 10-year median is 106.64 vs. the industry median of 65.79, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.79, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current Days Payable of 101.01 is 53.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current Days Payable is 101.01, which is near median its own 10-year median of 106.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current Days Payable of 101.01. The current Days Payable is 101.01, which is near median its 10-year median of 106.64 and 53.5% above the Medical Diagnostics & Research industry median of 65.79. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current Days Payable is 101.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
